Biotech Values

[mcbio]

CDTX -24% on phase-2 data with some questions

Just looking more into CDTX, what do you see as the biggest questions from this prior P2 data? I'm assuming it's the fact that the 400mg once on first week/200mg once each subsequent week out performed the 400mg/400mg arm so much. I guess the obvious question is why a much less potent dose on subsequent weeks would have much greater efficacy than the much higher dose. Is that your biggest concern? FWIW, it looks like the data in the 400mg/200mg looks good compared to the comparator arm.

I wonder if it has anything to do with patient selection in each arm. Anyways, the ongoing P3 trial appears to mirror that 400mg/200mg design so assuming they can replicate those results in P3, they should be in good shape I assume. Also, just as it relates to competitor drugs, I'm assuming a once weekly formulation would have advantages over a drug that needs to be taken daily.